Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
LENZ Therapeutics Inc(LENZ)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LENZ
09/25/2026: LENZ (1-star) is currently NOT-A-BUY. Pass it for now.
LENZ Therapeutics is a clinical-stage biotechnology firm dedicated to developing novel eye drop treatments for presbyopia. The company's main strength lies in its proprietary aceclidine-based platform, which has shown promise in late-stage clinical trials. Its primary investment story hinges on the potential for FDA approval and successful commercialization in a large, aging market. However, the company faces significant risks, including intense competition from established pharmaceutical players and the inherent dangers of clinical and regulatory failure. The stock may suit growth-oriented investors with a high risk tolerance who are looking for exposure to potential biotech breakthroughs, though they should closely monitor upcoming clinical and regulatory data.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | This is a high-risk growth play dependent on future clinical and regulatory success. |
| Momentum investor | Mixed fit | Momentum is highly conditional on positive clinical data readouts and potential regulatory breakthroughs. |
| Value investor | Weak fit | The company lacks earnings and historical cash flow metrics typical of value investments. |
| Dividend investor | Weak fit | LENZ is a growth-stage company that does not generate income for dividends. |
| Low-risk investor | Weak fit | The inherent risks of clinical-stage biotech make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is highly sensitive to binary clinical trial outcomes and regulatory news. |
| Valuation risk | Medium / high | Valuation is speculative and based on the projected commercial success of unapproved drugs. |
| Competition risk (pharmaceutical/ophthalmic) | High | The company must compete with well-capitalized incumbents with existing market distribution. |
| Business quality | Medium | The company is focused on a narrow pipeline, which increases concentration risk. |
| Dividend income | Low / none | The company does not provide income to shareholders. |
| Execution risk | High | Success depends entirely on achieving clinical endpoints and navigating complex FDA processes. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Highly Choppy
The stock has experienced frequent, large price swings that make its near-term movement less predictable.
Analysis of Past Performance
Type Stock | Historic Profit -7.68% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 116.88M USD | Price to earnings Ratio - | 1Y Target Price 24 |
Price to earnings Ratio - | 1Y Target Price 24 | ||
Volume (30-day avg) 694.2K shares | Beta 1.63 | 52 Weeks Range 3.60 - 50.40 | Updated Date 09/25/2026 |
52 Weeks Range 3.60 - 50.40 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -4.09 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Ophthalmic Drug Development | Clinical trial candidates like LNZ001 and LNZ002. | The company currently makes no money; it is burning cash to test drugs that it hopes to sell in the future. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value -101.29M | Price to Sales(TTM) 5.44 |
Enterprise Value -101.29M | Price to Sales(TTM) 5.44 | ||
Enterprise Value to Revenue 2.65 | Enterprise Value to EBITDA -7.99 | Shares Outstanding 31.42M | Shares Floating 18.39M |
Shares Outstanding 31.42M | Shares Floating 18.39M | ||
Percent Insiders 2.65 | Percent Institutions 111.8 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About LENZ Therapeutics Inc
Exchange NASDAQ | Headquarters Solana Beach, CA, United States | ||
IPO Launch date 2021-06-25 | President, CEO, Secretary & Director Mr. Evert B. Schimmelpennink | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://www.lenz-tx.com |
Full time employees 152 | Website https://www.lenz-tx.com | ||
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.